Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Next Previous
Trial Profile

Real world evidence (RWE) study of ZYTIGA (Abiraterone Acetate) plus prednisone for the treatment of asymptomatic and mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Feb 2017 New trial record
  • 17 Feb 2017 According to a Janssen media release, results from this study were presented at American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
  • 17 Feb 2017 Results published in the Janssen media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top